Back to top
more

Aurora Cannabis (ACB)

(Delayed Data from NSDQ)

$4.48 USD

4.48
1,765,197

+0.05 (1.13%)

Updated Aug 1, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Inogen (INGN) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Inogen's (INGN) first-quarter 2019 results are expected to get a boost from product launches.

Zacks Equity Research

What's in the Cards for Axon Enterprise (AAXN) Earnings?

by Zacks Equity Research

Axon Enterprise's (AAXN) expanded product offerings and strong execution likely to drive its first-quarter 2019 performance.

Zacks Equity Research

Can BD Medical Drive Becton, Dickinson's (BDX) Q2 Earnings?

by Zacks Equity Research

Becton, Dickinson (BDX) expects BD Medical to drive fiscal Q2 results; foreign exchange headwinds persist.

Zacks Equity Research

Can Core Business Unit Fuel McKesson (MCK) Q4 Earnings?

by Zacks Equity Research

Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.

Zacks Equity Research

What's in Store for Cardinal Health (CAH) in Q3 Earnings?

by Zacks Equity Research

Better-than-expected performance at Pharmaceutical and Medical segments and diverse product portfolio is likely to aid Cardinal Health (CAH) in Q3 earnings. However, stiff competition might play spoilsport.

Zacks Equity Research

The Zacks Analyst Blog Highlights: GW, Innovative Industrial, Canopy, Aurora and KushCo

by Zacks Equity Research

The Zacks Analyst Blog Highlights: GW, Innovative Industrial, Canopy, Aurora and KushCo

Zacks Equity Research

What's in the Cards for DaVita (DVA) This Earnings Season?

by Zacks Equity Research

Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.

Zacks Equity Research

Apyx Medical (APYX) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Apyx Medical (APYX) likely to gain from J-plasma technology in Q1; margins under pressure.

Zacks Equity Research

Can Dental Growth Drive Henry Schein's (HSIC) Q1 Earnings?

by Zacks Equity Research

Henry Schein (HSIC) is consistently riding on segmental strength at Dental, Medical and Technology plus Value-Added Services.

Nalak Das headshot

Invest Carefully in Rosy But Risky Marijuana Industry

by Nalak Das

The much-awaited Cannabis Banking Bill was finally passed by the House Financial Services Committee on Mar 28.

Zacks Equity Research

Can Steady CAG Growth Drive IDEXX's (IDXX) Q1 Earnings?

by Zacks Equity Research

Idexx (IDXX) is expected to continue reporting solid revenue growth on robust CAG performance.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.06, marking a +0.22% move from the previous day.

Zacks Equity Research

Can Breast Health Growth Drive Hologic's (HOLX) Q2 Earnings?

by Zacks Equity Research

Hologic's (HOLX) Breast Health segment is witnessing a rapid uptick on the back of large installed base of market-leading, clinically differentiated Genius 3D mammography systems.

Zacks Equity Research

Will Pharmacy Services Drive CVS Health's (CVS) Q1 Earnings?

by Zacks Equity Research

Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.

Zacks Equity Research

Is a Beat in the Offing for Humana's (HUM) Q1 Earnings?

by Zacks Equity Research

Humana's (HUM) Q1 earnings are likely to gain on higher membership and a solid Medicare Advantage.

Zacks Equity Research

Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?

by Zacks Equity Research

With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.

Zacks Equity Research

Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?

by Zacks Equity Research

Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.

Zacks Equity Research

Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?

by Zacks Equity Research

ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.

Zacks Equity Research

Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis

by Zacks Equity Research

Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis

Tracey Ryniec headshot

Should You Buy Lottery Stocks?

by Tracey Ryniec

Like playing the lottery, some stocks lure in investors with the promise of possible riches.

Zacks Equity Research

Can Front Line Care Drive Hill-Rom's (HRC) Q2 Earnings?

by Zacks Equity Research

Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.05, marking a -1.95% move from the previous day.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

by Urmimala Biswas

The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.

Sanghamitra Saha headshot

Likely Canopy-Acreage Deal Looks Good Enough to Boost ETF MJ

by Sanghamitra Saha

Canopy Growth will probably purchase the rights to buy Acreage Holdings to tap the growing potential of the U.S. marijuana market. This should bolster the ETF MJ.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) closed at $8.96 in the latest trading session, marking a +0.9% move from the prior day.